Seagen Inc.: Astellas and Seagen Receive Positive CHMP Opini

- If approved, PADCEV would be the first medicine for patients in the EU who have received prior platinum-based chemotherapy and a PD-1/L1 inhibitor Astellas Pharma Inc. (TSE:4503, President and CEO:

Related Keywords

Norway , Iceland , United States , California , Liechtenstein , Canada , Washington , Switzerland , Seattle , American , David Caouette , Kenji Yasukawa , Ahsan Arozullah , Peggy Pinkston , Chris Goldrick , Enfortumab Vedotin , American Society Of Clinical Oncology , Astellas Pharma Us Inc , European Commission , Portfolio Communications , Seagen Inc , Nasdaq , Exchange Commission , Astellas Pharma Inc , Corporate Communications , Most Common Adverse Reactions Including Laboratory Abnormalities , European Union , European Medicines Agency , European Union Member States , Committee For Medicinal Products Human Use , Medicinal Products , Human Use , Vice President , Medical Sciences Oncology , New England Journal , Important Safety , Toxic Epidermal Necrolysis , Common Adverse Reactions , Including Laboratory Abnormalities , Dualp Gp , Prescribing Information , Focus Area Approach , Quarterly Report , Accessed December , Bladder Cancer Factsheet , Previously Treated Advanced Urothelial , Astellas Pharma , Vedotin Antibody Drug Conjugate Targeting , Highly Potent Therapeutic Agent , Multiple Preclinical Cancer , Cancer Res , Advocacy Relations , Investor Relations , Seagen , Astellas , Eceive , Positive , Thmp , Opinion , Padcev , Nfortumab , Edotin , Ocally , Dvanced , Metastatic , Urothelial , Dancer ,